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Abstract Risk factors to explain the poor survival of
patients with osteosarcoma of the pelvis are poorly
understood. Therefore, we attempted to identify factors
affecting survival and development of local recurrence and
metastasis. We retrospectively reviewed 43 patients who
had high-grade pelvic tumors and were treated surgically.
Twenty lesions were chondroblastic, 10 fibroblastic, 11
osteoblastic, and one each was giant cell-rich and small
cell osteosarcomas. At a median of 3.5 years (range, 0.3–
21 years) postoperatively, 13 patients were alive with no
evidence of disease. The overall and disease-free 5-year
survival rates were 38% and 29%, respectively, at 5 years.
Anatomic location, tumor size, and margin predicted
survival. Fifteen patients (35%) had local recurrence. The
5-year cumulative incidence of recurrence with death as a
competing risk factor was 34%. Location in the ilium and
size of the tumor predicted local recurrence. Twenty-one
(49%) of 43 patients had metastases develop. The cumu-
lative incidence of metastasis with death as a competing
risk factor was 48% at 5 years. Six patients who presented
with metastasis had a worse survival than patients who had
no evidence of metastasis at presentation (2-year survival,
33% versus 76%). If distant metastasis is diagnosed sub-
sequent to primary treatment, aggressive therapy may be
justified.
Level of Evidence: Level II, prognostic study. See the
Guidelines for Authors for a complete description of levels
of evidence.
Introduction
Treating malignant tumors of the pelvis is one of the most
challenging problems for the orthopaedic oncologist
[5, 22]. Osteosarcoma of the pelvis accounts for 4% to 10%
of all osteosarcomas [12, 21]. These tumors are difficult to
resect because of their location, local extension, and large
size, and because of the complex regional and local anat-
omy and the difficulty in establishing functional
reconstructions that are durable and allow patients maxi-
mum function. Affected patients reportedly have a poor
outcome ranging from 4% to 32% [4, 6, 11, 18, 23, 25],
which is in stark contrast to the 70% to 75% 5-year survival
rate of patients with osteosarcoma of the extremities [8, 13,
14], The reason for this poor outcome is severalfold. Often,
there is a delay in diagnosis or a misdiagnosis, which
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usually is associated with a long duration of symptoms and
which may lead already to metastases before establishing
the diagnosis. Anatomically, there is poor compartmental-
ization in the pelvis because of the large size of these
lesions; they may cross the sacroiliac joint or involve the
pelvic veins [12]. This in turn makes it difficult to achieve a
wide margin. Furthermore, pelvic osteosarcomas are often
chondroblastic, a histologic subtype that responds only
poorly to chemotherapy [18, 25].
In the six largest series of pelvic osteosarcomas,
including between 25 and 67 patients, the 5-year survival
rate ranged from 4% to 32% [4, 6, 11, 18, 23, 25]. The rate
of secondary osteosarcomas in these series was as much as
33%, which also may contribute to the poor prognosis of
these patients. In the same series, the local recurrence rate
reportedly was between 11% and 62%, whereas the rate of
metastases was between 23% and 80% [4, 6, 11, 18, 23,
25]. The type of surgery and indication to perform surgery
for osteosarcoma of the pelvis may vary from institution to
institution. This makes it difficult to compare large series to
define prognostic parameters for this disease. Furthermore,
the risk factors or factors that may be correlated with dis-
ease progression in patients with operable osteosarcomas of
the pelvis are poorly understood.
We specifically asked (1) which risk factors affect sur-
vival, (2) which factors predict the rate of local recurrence,
and (3) which factors predict metastasis.
Materials and Methods
We retrospectively reviewed the records of all 43 patients
who underwent surgery for pelvic osteosarcomas at the
Mayo Clinic between 1983 and 2003. Several clinical
parameters were recorded and their influence on survival,
local recurrence, and metastasis were statistically assessed.
Seven patients we treated but who had previous surgical
treatment before their initial visit were excluded from this
review. Included in the study were 14 female patients and
29 male patients with a mean (standard deviation) age of
34.4 years (17.9 years) (range, 11–66 years) at the time of
diagnosis. No patients were seen specifically for this
review; none of our patients was lost to followup. After a
minimum duration of followup of 0.3 year (mean,
4.8 years; range, 0.3–21 years; median, 3.5 years), 13
(31%) patients were alive with no evidence of disease and
30 (69%) patients had died. We focused our analysis pri-
marily on survival and disease-free survival and
secondarily on local recurrence and metastasis. We
obtained prior Institutional Review Board approval.
The mean duration of symptoms was 6 months (range,
0–15 months). Sixteen osteosarcomas were located in the
ilium, nine at the sacroiliac joint, 10 in the acetabulum, five
in the ischium, two in the pubic bone, and one in the
sacrum. Histologic analyses revealed 20 chondroblastic, 10
fibroblastic, 11 osteoblastic, and one each giant cell-rich
and small cell osteosarcoma. All lesions were high-grade.
The etiology of 33 osteosarcomas was considered primary,
whereas 10 lesions were secondary, including one arising
in Paget’s disease and nine postirradiation osteosarcomas.
Of these, there were four cervical cancers and one each
lymphoma, rectal cancer, rhabdomyosarcoma of the pros-
tate, primitive neuroectodermal tumor, and angiosarcoma,
which initially were treated with radiation. The largest
diameter of these lesions averaged 9.6 cm (standard devi-
ation, 3.9 cm; range, 4–22 cm). Overall, 19 tumors were
10 cm or larger.
Based on imaging, if critical structures were involved
and an adequate margin could not be achieved, then
hemipelvectomy was performed. If there was involvement
of either the hip or the neurovascular structures, internal
hemipelvectomy was performed, whereas when two or
more of these structures were involved, external hemipel-
vectomy was done. We performed 29 (67%) internal and
14 (33%) external hemipelvectomies. We defined an ade-
quate margin (whether wide or marginal) as one with a cuff
of normal tissue around the tumor or one where the tumor
was covered by fascia separated easily from the sur-
rounding structures without any evidence of infiltration. By
this definition an adequate margin was achieved in 30
patients. An inadequate margin (intralesional) occurred in
13 patients (30%).
Followup included reevaluation of the patients at 3- to
4-month intervals for the first 2 years, at 6-month intervals
for the next 3 years, and once a year after 5 years. Clinic
visits were complemented by letters and questionnaires
provided by our institutional cancer registry. The ques-
tionnaires were related to general but not functional
information. For each patient, the etiology and size of the
lesion, type of resection, surgical margins, anatomic loca-
tion, histology, gender, age, radiotherapy, (neo)adjuvant
chemotherapy (adriamycin, cisplatin, high-dose metho-
trexate), local recurrence, metastasis, disease status at the
latest followup, and major complications associated with
treatment were collected and analyzed for each patient. We
(CYI) reviewed hematoxylin and eosin-stained sections
from each tumor. The number of slides available for review
ranged from four to 25 with a mean of 12 slides per case.
The histologic subtype was classified as chondroblastic,
osteoblastic, or fibroblastic and graded accordingly.
A power analysis was performed to determine the
smallest hazard ratios that could be detected with 80%
power among the potential risk factors studied. For the
primary outcome of survival, given the number of deaths
observed and the distribution of these events among the
potential risk factors studied, the smallest hazard ratio that
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could be detected with at least 80% power ranged from 2.8
to 4.5. Likewise, for disease-free survival, the smallest
hazard ratio that could be detected with at least 80% power
ranged from 2.7 to 3.6. Therefore, analyses of potential risk
factors with an observed hazard ratio less than 2.8 (for
survival) or less than 2.7 (for disease-free survival) would
be unlikely clinically important. Thus, the evaluations of
some potentially important risk factors were underpowered.
The analysis focused on the primary outcomes of sur-
vival and disease-free survival, the latter defined as
survival free of death, local recurrence, or metastasis.
Additional outcomes included local recurrence and
metastasis. Survival and disease-free survival rates for all
47 patients were estimated using the method of Kaplan and
Meier [17]. The rates of local recurrence and metastasis
were estimated by calculating the cumulative incidence of
these outcomes accounting for the competing risk of death
[10]. The effect of potential risk factors on survival and
disease-free survival were evaluated using Cox propor-
tional hazards models; the effects of local recurrence,
metastasis, and either recurrence or metastasis were mod-
eled as time-dependent covariates in the Cox models. To
graphically display the time-dependent effect of recurrence
or metastasis on survival, a landmark survival curve was
generated. A landmark of 18 months was chosen, and
patients were grouped according to whether they had local
recurrence or metastasis within the first 18 months after
surgery. The impact of potential risk factors on the out-
comes of recurrence and metastasis was evaluated using a
competing risk analysis in a Cox proportional hazards
model [10, 19] accounting for the competing risk of death.
Between-group comparisons of continuous nontime-to-
event outcomes (such as tumor necrosis rate) were per-
formed using Wilcoxon rank sum tests. All analyses were
performed using SAS1 Version 9.1 (SAS Institute Inc,
Cary, NC) and S-PLUS1 Version 8.0 (Insightful Corp,
Seattle, WA).
Results
The overall survival rate of the entire group was 38% at
5 years and 32% at 10 years (Fig. 1; Table 1). Location of
the lesion, recurrence, and metastasis were the most
important factors adversely affecting survival (Table 2).
Although tumor size of 10 cm or greater predicted survival
in the univariate model, it did not predict survival in the
multivariable model already containing tumor location and
the advent of metastasis and/or local recurrence, thus
confirming the primary importance of the latter variables
relative to tumor size. We observed worse survival among
patients with lesions located in the ilium versus other
locations (hazard ratio, 2.4; p = 0.03) and metastasis alone
or in combination with local recurrence (hazard ratio, 11.9;
p \ 0.001) (Table 2). The hazard ratios for these variables
in the multivariable model are similar to the hazard ratios
for each variable univariately, suggesting adjusting for one
or the other variable does not diminish the influence of the
other. Patients who had local recurrence or metastasis
within the first 18 months had worse (p = 0.003) survival
than those who did not (Fig. 2). The disease-free survival
rate of the entire group was 29% at 5 years and 26% at
10 years (Fig. 3; Table 1). Although inadequate margin
predicted survival when analyzed univariately, it did not
predict survival in a model containing a tumor size equal to
or greater than 10 cm. However, our analysis confirmed
tumor size of 10 cm or greater (hazard ratio, 3.2;
p = 0.004) is a major risk factor for poor disease-free
survival (Table 3). Survival of patients with chondroblastic
lesions was similar (p = 0.22) to survival of patients with
other types of lesions.
Tumor location and tumor size of 10 cm or greater were
major risk factors for development of local recurrence.
Fifteen (35%) of the 43 patients had local recurrence. If a
patient had a recurrence, none was alive at followup. The
cumulative incidence of recurrence with death as a com-
peting risk factor was 34% (95% confidence interval, 19%–
46%) at 5 years, showing all recurrences developed within
3 years after surgery (Fig. 4; Tables 4, 5). When death was
used as a competing risk factor, tumor location (ilium
versus other locations; hazard ratio, 2.1; p = 0.05) and
tumor size of 10 cm or greater (hazard ratio, 2.8;
p = 0.007) were identified as risk factors for the devel-
opment of local recurrence. Of patients who had an
Fig. 1 This Kaplan–Meier curve shows overall survival of the entire
group of patients who had surgery for an osteosarcoma of the pelvis.
Patients were censored at last known followup. The dotted curves
represent the 95% confidence interval. The 5-year survival rate of the
entire group was 38%. Location of the lesion, recurrence, and
metastasis were the most important factors adversely affecting
survival.
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adequate surgical margin, seven of 30 patients (23%) had
recurrence, whereas of patients with an inadequate margin,
eight of 13 patients (62%) had recurrence. Although the
hazard ratio for inadequate versus adequate margin was
1.99 (p = 0.12), the parameter is probably not an important
risk factor.
An inadequate margin and tumor size of 10 cm or greater
were major risk factors for development of metastasis. Six
patients presented with metastasis, and their survival was
worse (p = 0.004) than those who presented with no evi-
dence of metastasis (2-year survival, 33% versus 76%).
Twenty-one (49%) of 43 patients had subsequent
Table 1. Survival and disease-free survival estimates
Outcome Number Events 1-year rate* 2-year rate 5-year rate 10-year rate
Survival 43 30 0.837 (0.73–0.96) 0.721 (0.60–0.87) 0.381 (0.26–0.57) 0.318 (0.20–0.51)
Disease-free survival 40 31 0.675 (0.54–0.84) 0.475 (0.34–0.66) 0.294 (0.18–0.49) 0.261 (0.15–0.46)
* 95% confidence interval in parentheses.
Table 2. Survival by potential risk factor
Factor Level Number Events Hazard ratio 95% confidence interval p Value
Gender Female 14 9 1.00
Male 29 21 0.59 0.264–1.325 0.20
Age \ 30 years 22 14 1.00
C 30 years 21 16 1.07 0.501–2.281 0.86
Location Sacroiliac joint or other 27 17 1.00
Ilium 16 13 2.32 1.083–4.982 0.03
Location Ilium or other 34 26 1.00
Sacroiliac joint 9 4 0.47 0.164–1.367 0.17
Location Ilium 16 13 1.00
Sacroiliac joint 9 4 0.40 0.128–1.239 0.11
Maximum tumor size \ 10 cm 24 12 1.00
C 10 cm 19 18 2.63 1.255–5.518 0.01
Margins Adequate 30 19 1.00
Inadequate 13 11 1.57 0.742–3.334 0.24
Histology Other 23 16 1.00
Chondroblastic 20 14 0.62 0.287–1.321 0.21
Primary No 10 8 1.00
Yes 33 22 0.75 0.329–1.708 0.49
Extent of procedure Internal 29 19 1.00
External 14 11 1.05 0.499–2.224 0.89
Radiotherapy No 32 21 1.00
Yes 11 9 1.59 0.716–3.515 0.26
Chemotherapy No 7 5 1.00
Yes 36 25 2.00 0.73–5.475 0.18
Recurrence* No 1.00
Yes 15.50 6.5–37.0 \ 0.001
Metastasis* No 1.00
Yes 5.20 2.4–11.3 \ 0.001
Recurrence or metastasis* No 1.00
Yes 11.40 4.5–28.9 \ 0.001
Multivariable analysis
Recurrence or metastasis* Yes versus no 11.90 4.7–30.0 \ 0.001
Location Ilium versus other 2.38 1.1–5.3 0.03
* Analyzed as a time-dependent covariate.
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metastases. Eighteen (86%) of 21 patients who had metas-
tases were dead at the latest followup. The cumulative
incidence of metastasis with death as a competing risk factor
was 48% (95% confidence interval, 32%–61%) at 5 years.
Most of the metastases developed within 3 years after sur-
gery (Fig. 5; Table 4). Tumor size of 10 cm or greater
(hazard ratio, 2.9; p = 0.005) and an inadequate margin
(hazard ratio, 2.0; p = 0.06) were important risk factors for
metastasis with death as a competing risk factor (Table 6).
The mean tumor necrosis rate was 37.5% (standard
deviation, 35%; range, 0%–100%). As expected, the
necrosis rate was lower (p = 0.22) for chondroblastic
lesions (mean, 27%; standard deviation, 27.3%; range,
0%–98%) than for other types of lesions (mean, 47%;
standard deviation, 39.2%; range, 0%–100%).
Infection and local wound breakdown were the most
common complications that required de´bridement in 14
patients. One each colostomy and ileostomy and two cys-
tectomies were necessary because of lacerations during the
index surgery. There was one compartment syndrome of
the hand, which required decompression, a pseudomen-
ingocele, and a stroke and heart failure subsequent to
chemotherapy in one patient each.
Discussion
The overall survival of patients with an osteosarcoma of
the pelvis is considered to be poorer than that of patients
with extremity osteosarcoma. To improve the outcome of
these patients, risk factors need to be identified. A few
patients with pelvic osteosarcoma may be inoperable and
therefore may have a poorer prognosis per se. If these
patients are not separated from patients with operable
lesions and potentially better prognoses, we may reach
confounded conclusions. Our study therefore focuses on
patients with osteosarcoma of the pelvis with operable
lesions. We identified (1) which among a number of risk
factors influenced survival, (2) which factors predicted the
rate of local recurrence, and (3) which factors predicted
metastasis.
Limitations of our study include the retrospective nature
of our analysis assessing patients during a 20-year period.
During this time, surgical techniques evolved, and
improved imaging modalities such as CT and MRI allowed
precise delineation of the tumor from the surrounding
anatomic structures, which resulted in improved treatment
during the latter period of the study. Another limitation is,
given the size of the patient cohort and the number of
observed deaths, the power to detect differences was low
for some of the parameters studied. Therefore, the reader
needs to be aware, even in case of statistical significance,
the identified risk factors may not imply causal relationship
but only a correlation. However, these are uncommon
tumors and it is difficult to accumulate a large series from
one institution.
Our 5-year survival rate was 38% and at the high end of
comparable series in which it ranges from 4% to 32% [4, 6,
11, 18, 23, 25]. One explanation may be the comparably
lower local recurrence rate in this series and that we
included only patients who were operated on with a cura-
tive rather than palliative intent. Nevertheless, our results
suggest the survival of patients with pelvic osteosarcomas
is not comparable to the survival of patients with extremity
Fig. 2 This Kaplan–Meier survival curve shows overall survival
using an 18-month landmark. Patients were grouped into those who
had local recurrence or metastasis within the first 18 months and
those who were free of recurrence or metastasis at 18 months. This is
a graphic representation of the time-dependent effect of recurrence
and metastasis on survival. The dotted curves represent the 95%
confidence intervals. Patients who had metastasis develop within the
first 18 months had worse survival than those who did not.
Fig. 3 This Kaplan–Meier curve shows the disease-free survival rate
of the entire group. Patients were censored at last known followup.
The dotted curves represent the 95% confidence interval. The disease-
free survival rate of the entire group was 29%.
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lesions. Another reason for the poorer survival may be the
high rate of metastasis. In our series, 18% of all patients
were diagnosed with lung metastasis at initial presentation,
and 56% of all patients had metastasis develop during the
course of followup. This is comparable to other series
reporting an incidence between 26% and 63% [20, 25].
Several factors that may be responsible for metastasis have
been discussed, including surgical stage, histologic sub-
type, and type of surgical treatment. The high incidence of
metastasis at diagnosis is also comparable to that reported
by others [2, 12, 23, 25, 28], who noted osteosarcomas of
the trunk are more likely to have metastasized at diagnosis
than tumors of the extremity. Also reported by others [20],
the efficacy of chemotherapy was not a prognostic factor in
our series. Therefore, chemotherapy alone may not hinder
the development of metastasis in high-grade tumors of the
pelvis. As expected, patients without metastases had a
better 5-year survival rate than patients with metastases.
We further separated the patient group who had metastasis
develop into those who presented with or had metastasis
develop during initial treatment (neoadjuvant therapy,
Table 3. Disease-free survival by potential risk factor*
Factor Level Number Events Hazard ratio 95% confidence interval p Value
Gender Female 13 8 1.00
Male 27 23 1.02 0.449–2.321 0.96
Age \ 30 years 21 15 1.00
C 30 years 19 16 1.16 0.547–2.466 0.70
Location Sacroiliac joint or other 25 18 1.00
Ilium 15 13 1.65 0.782–3.474 0.19
Location Ilium or other 32 26 1.00
Sacroiliac joint 8 5 0.92 0.348–2.417 0.86
Location Ilium 15 13 1.00
Sacroiliac joint 8 5 0.72 0.254–2.025 0.53
Maximum tumor size \ 10 cm 21 12 1.00
C 10 cm 19 19 3.19 1.465–6.961 0.004
Margins Adequate 27 19 1.00
Inadequate 13 12 2.24 1.06–4.731 0.03
Histology Other 20 15 1.00
Chondroblastic 20 16 0.82 0.392–1.7 0.59
Primary No 8 7 1.00
Yes 32 24 0.75 0.317–1.768 0.51
Extent of procedure Internal 26 19 1.00
External 14 12 1.34 0.638–2.802 0.44
Radiotherapy No 29 21 1.00
Yes 11 10 1.30 0.603–2.795 0.50
Chemotherapy No 7 5 1.00
Yes 33 26 3.86 0.912–16.293 + F2 0.07
* After accounting for maximum tumor size 10 cm or greater, no other variables contributed substantially in the multivariable analysis of
disease-free survival.
Fig. 4 The cumulative incidence of recurrence is represented over
time with death as a competing risk. The dotted curves represent the
95% confidence intervals. The cumulative incidence of recurrence
rate was 34%, and they all occurred within 3 years after surgery.
Tumor location and tumor size of 10 cm or greater were major risk
factors for development of local recurrence.
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surgery, adjuvant therapy) and those who metastasis
develop subsequently. Our analysis showed patients with
metastasis present at diagnosis fared worse than patients
who had metastases develop after completion of treatment.
This also was described for patients with osteosarcoma of
the extremity [1]. This has several important consequences.
First, the similar biologic behavior with respect to metas-
tasis between extremity and axial osteosarcomas implies
these tumors, as often questioned, share the same biology,
regardless of their different survival. Therefore, we believe
there must be other parameters that account for the survival
disadvantage of patients with pelvic compared with
extremity osteosarcomas. Second, our results reveal, if
metastasis is diagnosed subsequent to initial treatment, the
prognosis is not fatal and may require aggressive combined
treatments because four of these patients in our series
survived.
We found tumor size, represented by the greatest tumor
dimension, predicted outcome and was negatively associ-
ated with the development of local recurrence and
metastasis. Nineteen patients (44%) had a tumor that was
10 cm or larger. This also may be reflected in the long
duration of symptoms until the diagnosis was established,
which averaged 6 months. This is longer than reported by
Ozaki et al. [23] (3.7 months), Bielack et al. (2.3 months)
[1], and Pollock et al. (1.9 months) [24]. Whereas in our
study and another [27], size was a major negative predictor
of outcome. Saab et al. [25] could not confirm this finding,
probably because of the small number of patients included
in their study. Because of the poor compartmentalization in
the pelvis, large tumors often have extraosseous extension
into gluteal muscles and/or involvement of the sciatic notch
area, which requires transection of the gluteal or internal
Table 4. Cumulative incidence of recurrence and metastasis with death as a competing risk
Outcome 1-year rate* 2-year rate* 5-year rate* 10-year rate*
Recurrence 0.167 (0.05–0.27) 0.286 (0.14–0.40) 0.338 (0.19–0.46) 0.338 (0.19–0.46)
Death (competing risk) 0.048 (0.00–0.11) 0.119 (0.00–0.22) 0.259 (0.08–0.40) 0.325 (0.12–0.48)
Metastasis 0.22 (0.09–0.33) 0.366 (0.21–0.49) 0.481 (0.32–0.61) 0.512 (0.34–0.64)
Death (competing risk) 0.073 (0–0.15) 0.098 (0–0.19) 0.243 (0.04–0.4) 0.243 (0.04–0.4)
* 95% confidence interval in parentheses.
Table 5. Recurrence with death as a competing risk by potential risk
factor
Factor Level Hazard
ratio
95%
confidence
interval
p Value
Gender Female 1.00
Male 0.68 0.28–1.69 0.41
Age \ 30 years 1.00
C 30 years 1.06 0.49–2.26 0.89
Location Sacroiliac
joint or other
1.00
Ilium 2.09 1–4.37 0.05
Location Ilium or other 1.00
Sacroiliac joint 0.51 0.15–1.73 0.28
Location Ilium 1.00
Sacroiliac joint 0.46 0.15–1.46 0.19
Maximum
tumor size
\ 10 cm 1.00
C 10 cm 2.75 1.31–5.77 0.007
Margins Adequate 1.00
Inadequate 1.99 0.84–4.67 0.12
Histology Other 1.00
Chondroblastic 0.73 0.34–1.53 0.4
Primary No 1.00
Yes 0.81 0.36–1.85 0.62
Extent of
procedure
Internal 1.00
External 1.14 0.55–2.35 0.72
Radiotherapy No 1.00
Yes 1.53 0.73–3.17 0.26
Chemotherapy No 1.00
Yes 2.01 0.99–4.08 0.052
Fig. 5 The cumulative incidence of metastasis is represented with
death as a competing risk factor. The dotted curves represent the 95%
confidence intervals. The cumulative incidence rate of metastasis was
48%, and the majority occurred within 3 years. An inadequate margin
and tumor size of 10 cm or greater were major risk factors for
development of metastasis.
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iliac vessels. This in turn may contribute to the high rate of
wound healing problems and infections as noted in our
patients. Widespread invasion into major pelvic veins is
reportedly a negative prognostic factor [6] but another
study found seven patients (of 40) with emboli in the
regional large vessels with a particularly poor prognosis
[18]. We did not routinely perform angiography and
intraoperatively we did not look for vascular invasion
because we performed external hemipelvectomy.
The goal of surgery is to achieve a wide margin.
However, because of the complex anatomy of the pelvis,
including the close association of large vessels and nerves
aligned in a complex manner around important visceral
organs with poor compartmentalization, this is difficult to
achieve. The overall local recurrence rate in our series was
34%, which is comparable to rates reported in other studies
[6, 18, 20, 23]. This may be surprising because all patients
included in our study were treated with a locally curative
intent. In accordance with those reported studies, surgical
margin was also a predictor of local recurrence. All
patients who had local recurrence in our study were dead at
the latest followup. Numerous authors have reported sacral
involvement of the primary tumor or an ilium lesion
crossing the sacroiliac joint is the most important predictor
of development of local recurrences [3, 5, 6, 11, 12, 18,
26]. Our results confirm these findings only partly because
this anatomic location was not a major predictor for the
development of local recurrence and/or metastasis. How-
ever, the ilium was a negative predictor of overall survival.
Moreover, our results imply it is possible to achieve ade-
quate margins in this difficult pelvic area, which is in line
with a previous report from our institution [9]. Internal
hemipelvectomy has become more popular than classic
external hemipelvectomy [15, 23]. As others have shown,
the survival of patients who underwent either external or
internal hemipelvectomy did not differ in our series [4]. As
a consequence, considering the risk of death after local
recurrence, external hemipelvectomy may be chosen for
patients in whom limb-salvage surgery may be associated
with an inadequate surgical margin.
In 20 patients (46%), the tumor histology was
chondroblastic. The high incidence of this histologic sub-
type is consistent with the observation of others that the
chondroblastic subtype has a greater tendency to involve
the trunk [2, 12, 18], with 36% to 58% of pelvic osteo-
sarcomas being chondroblastic. This is in contrast to
reported series for osteosarcoma of the extremities, in
which the majority of tumors are osteoblastic [25]. There
were many secondary pelvic osteosarcomas in our series,
which parallels the findings of Grimer et al. [11] and Saab
et al. [25], who found an incidence of 33% and 21%,
respectively, in their series. This is higher than the 4%
incidence of irradiation-related osteosarcomas reported for
all sites [7]. Irradiation-associated osteosarcoma and os-
teosarcomatous transformation in Paget’s disease or fibrous
dysplasia generally were associated with poorer prognosis
[7]. Whereas Grimer et al. [11] reported none of their
patients with secondary osteosarcoma was alive after
29 months, we were not able to detect a difference in our
series between the survival of patients with primary versus
secondary tumors. Based on our results and others [1, 25],
we believe, provided local tumor control is achieved and
adjuvant therapy applied, these patients may have a prog-
nosis similar to that of patients with otherwise comparable
primary osteosarcoma [16].
The overall survival rate of patients with osteosarcoma
of the pelvis does not reach the survival rate of patients
with extremity osteosarcomas. Anatomic location, local
recurrence, and metastasis are adverse parameters of sur-
vival. The size of the lesion negatively influenced the
occurrence of metastasis and local recurrence, whereas an
inadequate margin was important for development of
metastasis, and anatomic location was an important pre-
dictor for development of local recurrence. Patients with
Table 6. Metastasis with death as a competing risk by potential risk
factor
Factor Level Hazard
ratio
95%
confidence
interval
p Value
Gender Female 1.00
Male 0.96 0.42–2.21 0.92
Age \ 30 years 1.00
C 30 years 1.20 0.57–2.5 0.63
Location Sacroiliac
joint or other
1.00
Ilium 1.67 0.85–3.28 0.14
Location Ilium or other 1.00
Sacroiliac joint 0.95 0.34–2.66 0.92
Location Ilium 1.00
Sacroiliac joint 0.72 0.24–2.13 0.55
Maximum
tumor size
\ 10 cm 1.00
C 10 cm 2.85 1.38–5.9 0.005
Margins Adequate 1.00
Inadequate 2.00 0.96–4.15 0.06
Histology Other 1.00
Chondroblastic 0.76 0.38–1.53 0.44
Primary No 1.00
Yes 0.73 0.32–1.64 0.44
Extent of
procedure
Internal 1.00
External 1.37 0.68–2.76 0.38
Radiotherapy No 1.00
Yes 1.32 0.66–2.62 0.43
Chemotherapy No 1.00
Yes 3.73 0.79–17.64 0.10
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local recurrence and the presence of metastasis at diagnosis
have a poor outcome; patients diagnosed with metastasis
subsequent to treatment or without metastasis have a better
survival rate and aggressive adjuvant therapy may be
justified.
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